CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,558 | -24.1% | 34,331 | -6.1% | 0.02% | -11.8% |
| Q2 2023 | $2,053 | -14.1% | 36,563 | -30.8% | 0.02% | -15.0% |
| Q1 2023 | $2,389 | +131.0% | 52,820 | +107.6% | 0.02% | +33.3% |
| Q4 2022 | $1,034 | -99.9% | 25,441 | +47.7% | 0.02% | 0.0% |
| Q3 2022 | $1,125,000 | -4.3% | 17,220 | +10.9% | 0.02% | +25.0% |
| Q4 2021 | $1,176,000 | +13.6% | 15,522 | +67.9% | 0.01% | -14.3% |
| Q3 2021 | $1,035,000 | +238.2% | 9,246 | +267.8% | 0.01% | +250.0% |
| Q1 2021 | $306,000 | -65.8% | 2,514 | -57.0% | 0.00% | -55.6% |
| Q4 2020 | $894,000 | +237.4% | 5,842 | -6.4% | 0.01% | -40.0% |
| Q1 2020 | $265,000 | – | 6,242 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |